In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders.
The journal publishes timely in-depth/mini reviews, research article and drug clinical trial studies in the field of signal transduction therapy. Thematic issues are also published to cover selected areas of signal transduction therapy. Coverage of the field includes genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases. Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.
Jingxuan Yang The University of Oklahoma Health Science Center Oklahoma City, OK USA
Dr. Yang obtained a doctorate (Ph.D.) in Molecular Biology & Biochemistry from Chinese Academy of Med. Sci. and Peking Union Med. College (CAMS & PUMC), Beijing, China. Currently Dr. Yang is an assistant professor in the University of Oklahoma Health Sciences Center. He has published more than 30 scientific publications and served as active editorial board member of Scientific Reports.
Dr. Yang is currently the Editor-in-Chief of this journal (Current Signal Transduction Therapy), published by Bentham Science Publishers.